Yokogawa and Repligen Partner to Advance Real-Time Bioprocess Monitoring Technology
核心洞察
Yokogawa Corporation of America (搜索) and Repligen (搜索) have announced a collaboration to integrate OpreX Bio Pilot (搜索) with MAVERICK (搜索)® for enhanced automated control of glucose and lactate (搜索) levels in cell cultures.
The partnership enables continuous, real-time analysis of critical bioprocess parameters without manual sampling or complicated calibration models, supporting improved data management.
The integration aims to minimize batch failures, improve productivity, and reduce time to market for biopharmaceutical product development.
Yokogawa Corporation of America (搜索) and Repligen (搜索) have announced a strategic collaboration to integrate advanced process analytical technology platforms, combining Yokogawa's OpreX Bio Pilot (搜索) with Repligen's MAVERICK (搜索)® system to enhance automated control of glucose and lactate (搜索) levels in cell cultures. The partnership represents a significant advancement in bioprocess automation, enabling real-time monitoring of critical process parameters without the complexity of traditional analytical workflows.
Technology Integration and Capabilities
The combined solution allows scientists in process development to measure critical process parameters in bioprocessing without building complicated calibration models. This integration enables continuous, real-time analysis without manual sampling and supports effective data management, addressing key challenges in biopharmaceutical manufacturing.
The MAVERICK (搜索)® platform represents the first Raman-based product that is turn-key and built specifically for bioprocess analytics. According to Chris Brown, VP Research & Development Analytics of Repligen (搜索), "It is the first Raman-based product that is turn-key and built for bioprocess analytics, and the Yokogawa team was very quick to see the advantages of incorporating this platform in their automation solution."
Clinical and Commercial Impact
In bioprocessing, continuous monitoring of glucose and lactate (搜索) levels is crucial for optimizing cell culture conditions and advancing the research and development of biopharmaceutical products. Accurate measurement of these parameters allows for better control of the bioreactor environment, minimizing batch failures, leading to improved productivity and reduced time to market.
Mai Hagimoto, Life Sciences Director at Yokogawa Corporation of America (搜索), emphasized the significance of the partnership: "By integrating MAVERICK (搜索) with OpreX Bio Pilot (搜索), we are enabling real-time, in-line monitoring of critical process parameters with unprecedented accuracy and efficiency. This joint solution simplifies complex analytical workflows and supports data-driven decision-making in cell culture optimization."
Development and Validation Timeline
The combined solution is currently being demonstrated at both Yokogawa Electric Corporation's laboratory in Tokyo, Japan and Repligen (搜索)'s facility in Waltham, MA. Additional studies are planned at these laboratories and other institutions to further validate the integrated platform's capabilities.
Initial scientific data from this collaboration bridging real-time analytics and intelligent, digital bioprocessing will be presented by Yokogawa during the forthcoming BioProcess International conference on September 17th, 2025. This presentation will provide the first public demonstration of the partnership's technical achievements and potential applications in biopharmaceutical manufacturing.
The collaboration aims to contribute meaningfully to accelerating biopharmaceutical development and enhancing operational excellence across the industry by providing cutting-edge solutions that empower biopharma customers with advanced bioprocess analytics capabilities.